Celyad SA (CYAD): Price and Financial Metrics
GET POWR RATINGS... FREE!
CYAD Stock Price Chart Interactive Chart >
CYAD Price/Volume Stats
| Current price | $1.29 | 52-week high | $3.63 |
| Prev. close | $1.57 | 52-week low | $0.46 |
| Day low | $1.26 | Volume | 150,700 |
| Day high | $1.43 | Avg. volume | 5,026,494 |
| 50-day MA | $1.04 | Dividend yield | N/A |
| 200-day MA | $1.59 | Market Cap | 29.15M |
Celyad SA (CYAD) Company Bio
Celyad SA is a leader in engineered cell therapy treatments with clinical programs initially targeting indications in cardiology and oncology. The company was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.
Latest CYAD News From Around the Web
Below are the latest news stories about CELYAD ONCOLOGY SA that investors may wish to consider to help them evaluate CYAD as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayIt's the final day of trading this week and we're checking in on the biggest pre-market stock movers for Friday morning! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayWe're starting the day with a breakdown of the biggest pre-market stock movers traders will want to watch on Wednesday morning! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayWe're starting off Tuesday with a look at the biggest pre-market stock movers that traders will want to keep an eye on today! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayWe're starting off the day with a breakdown of the biggest pre-market stock movers traders need to keep an eye on for Thursday! |
Celyad Oncology Completely Shifts To Preclinical Stage, Pulls Plug On Only Human Trial AssetCelyad Oncology (NASDAQ: CYAD) provides an update on its Celyad 2.0 business strategy, which has been adopted and implemented over the last few months. The company has compiled a foundational and broad IP estate. In addition to IP partnering transactions, Celyad 2.0 will prioritize discovery research in areas including: Multiplexing approach of the short hairpin RNA (shRNA) platform. Dual CAR development of a next-generation NKG2D-based CAR. Development of B7-H6-targeting immunotherapies for sev |
CYAD Price Returns
| 1-mo | 153.94% |
| 3-mo | 18.35% |
| 6-mo | -47.35% |
| 1-year | -61.61% |
| 3-year | -88.80% |
| 5-year | -97.29% |
| YTD | 161.72% |
| 2022 | -86.53% |
| 2021 | -53.08% |
| 2020 | -25.14% |
| 2019 | -42.62% |
| 2018 | -57.87% |
Continue Researching CYAD
Want to see what other sources are saying about Celyad Sa's financials and stock price? Try the links below:Celyad Sa (CYAD) Stock Price | Nasdaq
Celyad Sa (CYAD) Stock Quote, History and News - Yahoo Finance
Celyad Sa (CYAD) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...